Sanofi Financial Statements From 2010 to 2024
| SNYNF Stock | USD 94.25 1.55 1.67% |
Check Sanofi financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sanofi main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Sanofi financial statements analysis is a perfect complement when working with Sanofi Valuation or Volatility modules.
Sanofi |
Sanofi Company Return On Equity Analysis
Sanofi's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sanofi Return On Equity | 0.0959 |
Most of Sanofi's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sanofi is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Sanofi has a Return On Equity of 0.0959. This is 100.4% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The return on equity for all United States stocks is 130.94% lower than that of the firm.
Sanofi Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sanofi's current stock value. Our valuation model uses many indicators to compare Sanofi value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sanofi competition to find correlations between indicators driving Sanofi's intrinsic value. More Info.Sanofi is currently regarded as top stock in return on equity category among related companies. It is currently regarded as top stock in return on asset category among related companies reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sanofi is roughly 1.58 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sanofi by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sanofi's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sanofi's earnings, one of the primary drivers of an investment's value.About Sanofi Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Sanofi income statement, its balance sheet, and the statement of cash flows. Sanofi investors use historical funamental indicators, such as Sanofi's revenue or net income, to determine how well the company is positioned to perform in the future. Although Sanofi investors may use each financial statement separately, they are all related. The changes in Sanofi's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sanofi's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Sanofi Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Sanofi. Please read more on our technical analysis and fundamental analysis pages.
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi-Aventis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 95442 people.
Currently Active Assets on Macroaxis
Check out the analysis of Sanofi Correlation against competitors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Sanofi Pink Sheet analysis
When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |